Trial Profile
A Phase Ib/II, Open-label, Multicenter Study of Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Oleclumab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms COLUMBIA-1
- Sponsors AstraZeneca AB; MedImmune
- 13 Nov 2023 Status changed from completed to discontinued.
- 10 Mar 2023 Status changed from active, no longer recruiting to completed.
- 04 Sep 2022 The trial has been discontinued in Spain, according to European Clinical Trials Database